The company also announced its intention to acquire Genomic Health in a $2.8 billion deal.
Here’s what you should know:
1. Approximately 415,000 Cologuard tests were completed in the quarter, a 93 percent year-over-year increase.
2. More than 13,000 clinicians ordered Cologuard for the first time in the quarter.
3. Exact posted a net loss of $38.4 million, or $0.30 per share, in the quarter.
4. Exact made $479 in revenues per test, while cost per test dropped to $123, a $2 year-over-year improvement.
5. Exact raised its 2019 outlook to between $800 million and $810 million from $725 million to $740 million.
Company chairman and CEO Kevin Conroy said: “The Exact Sciences team delivered another strong quarter, bringing us closer to our goal of capturing at least 40-percent share of the U.S. colorectal cancer screening market with Cologuard, from about 6 percent today. The foundation we’ve built with our team, infrastructure, and commercial scale positions Exact Sciences well for continued growth.”
More articles on anesthesia:
Managing anesthesia services in ASCs — 5 top problems + solutions
5 questions to ask ASC anesthesia providers
CRH Medical acquires Florida gastroenterology anesthesia practice — 3 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
